SB-3CT (CAS 292605-14-2)
See product citations (15)
QUICK LINKS
SB-3CT is a selective inhibitor of matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9), enzymes that are implicated in the breakdown of extracellular matrix components and are known to play a role in angiogenesis, tumor growth, and metastasis. As such, SB-3CT is frequently used in cancer research to understand the contribution of these enzymes to the invasive behavior of cancer cells. By inhibiting MMP activity, SB-3CT helps in delineating the molecular events that drive tumor progression and provides a means to explore potential strategies for inhibiting cancer dissemination. Additionally, this compound is used in the investigation of tissue remodeling and wound healing processes, as MMPs are critical in the degradation and reconstitution of the extracellular matrix during these biological events. SB-3CT′s specificity for MMP-2 and MMP-9 also makes it an important tool in the study of conditions where these enzymes are dysregulated.
SB-3CT (CAS 292605-14-2) References
- X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. comparison with the latent and active forms of the enzyme. | Kleifeld, O., et al. 2001. J Biol Chem. 276: 17125-31. PMID: 11278946
- Complex pattern of membrane type 1 matrix metalloproteinase shedding. Regulation by autocatalytic cells surface inactivation of active enzyme. | Toth, M., et al. 2002. J Biol Chem. 277: 26340-50. PMID: 12004057
- Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity. | Solomon, A., et al. 2004. J Biol Chem. 279: 31646-54. PMID: 15102849
- A convenient synthesis of a selective gelatinase inhibitor as an antimetastatic agent. | Lim, IT., et al. 2004. J Org Chem. 69: 3572-3. PMID: 15132575
- Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. | Krüger, A., et al. 2005. Cancer Res. 65: 3523-6. PMID: 15867341
- Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. | Bonfil, RD., et al. 2006. Int J Cancer. 118: 2721-6. PMID: 16381009
- Metabolism of a highly selective gelatinase inhibitor generates active metabolite. | Lee, M., et al. 2007. Chem Biol Drug Des. 70: 371-82. PMID: 17927722
- MMP cellular responses to dengue virus infection-induced vascular leakage. | Luplertlop, N. and Missé, D. 2008. Jpn J Infect Dis. 61: 298-301. PMID: 18653973
- DFT studies of the ring-opening mechanism of SB-3CT, a potent inhibitor of matrix metalloproteinase 2. | Tao, P., et al. 2009. Org Lett. 11: 2559-62. PMID: 19445474
- QM/MM Studies of the Matrix Metalloproteinase 2 (MMP2) Inhibition Mechanism of (S)-SB-3CT and its Oxirane Analogue. | Zhou, J., et al. 2010. J Chem Theory Comput. 6: 3580-3587. PMID: 21076643
- MMP-9 inhibitor SB-3CT attenuates behavioral impairments and hippocampal loss after traumatic brain injury in rat. | Jia, F., et al. 2014. J Neurotrauma. 31: 1225-34. PMID: 24661104
- LPS Induces Occludin Dysregulation in Cerebral Microvascular Endothelial Cells via MAPK Signaling and Augmenting MMP-2 Levels. | Qin, LH., et al. 2015. Oxid Med Cell Longev. 2015: 120641. PMID: 26290681
- Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1. | Ye, Y., et al. 2020. Genome Med. 12: 83. PMID: 32988398
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SB-3CT, 1 mg | sc-205847 | 1 mg | $102.00 | |||
SB-3CT, 5 mg | sc-205847A | 5 mg | $388.00 |